Indivior (NASDAQ:INDV) Reports Strong Trading Volume - Is It Time to Invest?

Indivior PLC (NASDAQ:INDV) experienced a notable spike in trading activity on Friday, with around 419,314 shares exchanged during mid-day trading. This reflects a 6% increase from the preceding day's volume of 396,994 shares. The stock was last seen trading at $7.58, down from its prior closing price of $7.98.

Growth Potential According to Analysts

Recent reports from several research analysts have provided valuable insights into Indivior's prospects. On Friday, Craig Hallum adjusted their price target for Indivior, reducing it from $20.00 to $16.00, while maintaining a "buy" rating. Similarly, Piper Sandler reaffirmed their "overweight" rating, issuing a new target price of $15.00, down from a previous estimate of $22.00.

Indivior's Stock Performance Overview

Evaluating the company's financials reveals a debt-to-equity ratio of 23.50, with a quick ratio of 0.68 and a current ratio of 0.85. Indivior carries a market capitalization of $1.02 billion and has a P/E ratio of 759.00, coupled with a beta of 0.68. Over the past months, the company's 50-day moving average stands at $11.11, while the 200-day moving average is $14.80.

Indivior’s latest quarterly earnings, announced on July 25th, showed that the company reported earnings per share (EPS) of $0.44, which exceeded analysts' expectations of $0.40 by $0.04. Despite achieving this, the firm recorded a negative net margin of 12.29% and an exceptionally high negative return on equity of 654.82%. The company's revenue for the quarter was $299.00 million, surpassing the consensus estimate of $285.90 million. Analysts project that Indivior PLC will post earnings of 1.7 per share for the ongoing fiscal year.

Institutional Investors' Movements

Recent changes in positions by institutional investors and hedge funds in Indivior are noteworthy. M&G Plc initiated a new stake in the company in the first quarter, purchasing shares worth around $2,518,000. Meanwhile, Janus Henderson Group PLC increased its holdings by 14.2%, owning 440,121 shares valued at approximately $9,424,000 after acquiring an additional 54,750 shares. Vanguard Group Inc. also raised its stake by 0.9% in the fourth quarter, owning 5,899,190 shares worth $90,081,000 following an increase of 52,836 shares. Quadrature Capital Ltd. made a new investment during the first quarter for around $1,523,000, while Susquehanna International Group Ltd. participated in the second quarter with a stake valued at $3,224,000. Overall, institutional and hedge fund investors collectively hold 60.33% of Indivior's stock.

Overview of Indivior's Operations

Indivior PLC focuses on the development, manufacturing, and sale of buprenorphine-based prescription medications designed to treat opioid dependence and related disorders in various regions, including the United States and the United Kingdom. The company's initiatives target various substance use disorders, critical mental illnesses, and opioid overdoses.

Is It Time to Invest in Indivior?

Considering the current situation surrounding Indivior and the analysts' insights, potential investors may wonder if now is the right moment to buy shares. While the stock holds a "Buy" rating from some analysts, it’s essential to analyze other investment options as several top-rated analysts are recommending alternative stocks.

Market research indicates a list of five stocks that analysts suggest may offer better investment opportunities than Indivior. Before making any investment decisions, potential investors should review this information carefully.

Indivior, Stocks, Investing